Effective immediately Lipigon is announcing Dr. Gisela Sitbon as new Chairman of the Board. She is replacing Lars Öhman who will stay as member of the Board of Directors. Sitbon is currently Chairman of the Board at Beactica and stock exchange listed Nanologica. Lipigon is also welcoming Dr. Erik Lund as a new board member. Lund has more than 15 years of experience from the big pharma industry, most recently as director of business development at MSD.

"Bringing in these experienced external board members is an important step in the process of building a sustainable research based company. Gisela Sitbon has been involved in the life science industry at senior level for well over 25 years. She has vast experience from early stage companies and she has recently taken part in bringing two companies to the stock market. Erik Lund brings the sought after big pharma perspective to Lipigon and will play an important role in Lipigon's strategic development. These are two strong additions to the Board of Directors that I think complement the existing board very well." said CEO and Lipigon co-founder Stefan K Nilsson.

"I am honored to be nominated as new Chairman of the Board. Lipigon is an exciting company with a vision to make its mark within the field of lipid biology. They already achieved a research collaboration with AstraZeneca last year. I am looking forward to working with the Lipigon team and help them fine tune the strategy for the future." said Gisela Sitbon, new Chairman of the Board.

For further information, please contact:

Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals
Tel: +46 70 578 17 68

About Lipigon

Lipigon is a spin out from Umeå University in Sweden. The company was founded by leading scientists in the field of cellular lipid transport. Lipigon is currently focusing on the discovery and development of novel treatments for dyslipidemia and metabolic diseases. For more information please visit:


Lipigons VD Dr. Stefan K Nilsson väljs in i The European Lipoprotein Club (ELC), det äldsta och mest aktiva europeiska nätverket inom lipidfältet. ELC etablerades 1977 för att främja samarbete och utbyte av idéer inom grundforskning och klinisk forskning på lipoproteiner (blodfettskomplex).


Lipigon Pharmaceuticals ("Lipigon") tillkännagav idag att bolaget har tecknat avtal avseende validering av målprotein för läkemedelsutveckling med Secarna Pharmaceuticals ("Secarna") som är specialiserat på RNA-behandlingar genom s.k. antisens-teknologi. Målet är att tillsammans utveckla ett läkemedel som är best-in-class för behandling av allvarliga former av dyslipidemi (allmänna blodfettsrubbningar) och närliggande sjukdomar.


Lipigon Pharmaceuticals ("Lipigon") announced today that it has entered into a Target Validation Research Agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals ("Secarna"). The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.


Starting December 2016 Lipigon joins the AZ BioVentureHub located at AstraZeneca's site in Mölndal, Sweden. The contract stretches over 1 year giving Lipigon an office and full access to the whole facility, including infrastructure and capabilities.


Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.


Lipigon Pharmaceuticals today announced that it has entered into a research collaboration with AstraZeneca to conduct joint research to identify drug candidates that promote the stabilization of Lipoprotein Lipase (LPL) and may have utility in the treatment of lipid disorders and cardiovascular disease.


UMEÅ, November 18th. Lipigon Pharmaceuticals and AstraZeneca enter research collaboration to develop a high throughput assay for the identification of molecules that modulate lipoprotein lipase activity



11 juli, 2022, Pressmeddelande

Sista dag för handel med BTA i Lipigon

Företrädesemissionen i Lipigon Pharmaceuticals AB (publ) ("Bolaget" eller "Lipigon") är nu registrer...

21 juni, 2022, Pressmeddelande

Lipigon tillförs 22,6 MSEK i emissionslikvid

Lipigon Pharmaceuticals AB (publ) ("Bolaget" eller "Lipigon") meddelar härmed utfallet i den företrä...

13 juni, 2022, Pressmeddelande

Lipigons vd om emissionen och den nystartade fas I-studien

Lipigon beslutade i maj om en nyemission av aktier om drygt 21 MSEK med företrädesrätt för Lipigons ...